ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of a Purified Standardised Bee Venom Preparation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00263952
Recruitment Status : Completed
First Posted : December 12, 2005
Last Update Posted : March 4, 2013
Sponsor:
Information provided by (Responsible Party):
Allergopharma GmbH & Co. KG

Brief Summary:
The trial is performed to assess efficacy and safety of a purified standardised bee venom preparation in bee venom allergy

Condition or disease Intervention/treatment Phase
Bee Venom Allergy Biological: bee venom Phase 3

Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Immunotherapy of Bee Venom Allergy: Evaluation of a New Purified Bee Venom Preparation in Comparison With Already Published Studies.
Study Start Date : March 2003
Actual Primary Completion Date : January 2005
Actual Study Completion Date : April 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy
U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of bee venom allergy,
  • Positive RAST for bee venom,
  • Positive skin prick test for bee venom

Exclusion Criteria:

  • Serious chronic diseases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00263952


Locations
Germany
Allergopharma GmbH & Co. KG
Reinbek, Germany, 21465
Sponsors and Collaborators
Allergopharma GmbH & Co. KG
Investigators
Principal Investigator: Annemie Narkus, M.D.

Additional Information:
Responsible Party: Allergopharma GmbH & Co. KG
ClinicalTrials.gov Identifier: NCT00263952     History of Changes
Other Study ID Numbers: Al0202ig
First Posted: December 12, 2005    Key Record Dates
Last Update Posted: March 4, 2013
Last Verified: March 2013

Keywords provided by Allergopharma GmbH & Co. KG:
Bee venom allergy
Specific immunotherapy

Additional relevant MeSH terms:
Hypersensitivity
Immune System Diseases